338 related articles for article (PubMed ID: 32931024)
1. Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience.
Ghirardi V; Ronsini C; Trozzi R; Di Ilio C; Di Giorgio A; Cianci S; Draisci G; Scambia G; Fagotti A
Cancer; 2020 Dec; 126(24):5256-5262. PubMed ID: 32931024
[TBL] [Abstract][Full Text] [Related]
2. Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
Gruner M; Chambers LM; Yao M; Chichura A; Morton M; Costales AB; Horowitz M; Rose PG; Debernardo R; Michener CM
Gynecol Oncol; 2021 Sep; 162(3):645-651. PubMed ID: 34247768
[TBL] [Abstract][Full Text] [Related]
3. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
[TBL] [Abstract][Full Text] [Related]
4. HIPEC after neoadjuvant chemotherapy and interval debulking is associated with development of platinum-refractory or -resistant disease.
Jou J; Zimmer Z; Charo L; Yau C; Saenz C; Eskander R; McHale M; Veerapong J; Plaxe S; Binder P
Gynecol Oncol; 2021 Apr; 161(1):25-33. PubMed ID: 33293046
[TBL] [Abstract][Full Text] [Related]
5. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
[TBL] [Abstract][Full Text] [Related]
6. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
[TBL] [Abstract][Full Text] [Related]
7. Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?
Ghirardi V; De Felice F; D'Indinosante M; Bernardini F; Giudice MT; Fagotti A; Scambia G
Cancer Treat Res Commun; 2022; 31():100518. PubMed ID: 35065323
[TBL] [Abstract][Full Text] [Related]
8. A Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy in Primary Advanced Ovarian Cancer: The First Reported Pilot Experience from Saudi Arabia.
Abu-Zaid A; Alomar O; Alsabban M; Salem H; Al-Badawi IA
Gulf J Oncolog; 2020 Sep; 1(34):19-25. PubMed ID: 33431358
[TBL] [Abstract][Full Text] [Related]
9. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery.
El Hajj H; Vanseymortier M; Hudry D; Bogart E; Abdeddaim C; Leblanc E; Le Deley MC; Narducci F
ESMO Open; 2021 Apr; 6(2):100098. PubMed ID: 33819750
[TBL] [Abstract][Full Text] [Related]
10. Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes.
Ghirardi V; Trozzi R; Scanu FR; Giannarelli D; Santullo F; Costantini B; Naldini A; Panico C; Frassanito L; Scambia G; Fagotti A
Ann Surg Oncol; 2024 May; 31(5):3350-3360. PubMed ID: 38411761
[TBL] [Abstract][Full Text] [Related]
11. To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy.
Kumari A; Thakur M; Saha SC; Suri V; Prasad GRV; Patel FD; Radhika S
J Obstet Gynaecol; 2021 May; 41(4):616-620. PubMed ID: 32811236
[TBL] [Abstract][Full Text] [Related]
12. Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study.
He X; Wei L; Li R; Jing S; Jia L; Ji D; Li Y; Wang Y; Zhu Y
BMC Cancer; 2021 Jun; 21(1):738. PubMed ID: 34176478
[TBL] [Abstract][Full Text] [Related]
13. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
14. Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry.
Chambers LM; Yao M; Morton M; Chichura A; Costales AB; Horowitz M; Gruner MF; Rose PG; Michener CM; DeBernardo R
Int J Gynecol Cancer; 2021 Jul; 31(7):1021-1030. PubMed ID: 34006567
[TBL] [Abstract][Full Text] [Related]
15. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy.
Lee JY; Lee YJ; Son JH; Kim S; Choi MC; Suh DH; Song JY; Hong DG; Kim MK; Kim JH; Chang SJ
JAMA Surg; 2023 Nov; 158(11):1133-1140. PubMed ID: 37672264
[TBL] [Abstract][Full Text] [Related]
17. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
[TBL] [Abstract][Full Text] [Related]
18. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update.
Revaux A; Carbonnel M; Kanso F; Naoura I; Asmar J; Kadhel P; Ayoubi JM
Horm Mol Biol Clin Investig; 2020 Feb; 41(3):. PubMed ID: 32083444
[TBL] [Abstract][Full Text] [Related]
19. State of the Science: The role of HIPEC in the treatment of ovarian cancer.
Dellinger TH; Han ES
Gynecol Oncol; 2021 Feb; 160(2):364-368. PubMed ID: 33419611
[No Abstract] [Full Text] [Related]
20. Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study.
Lee YJ; Lee JY; Cho MS; Nam EJ; Kim SW; Kim S; Kim YT
J Gynecol Oncol; 2019 Jan; 30(1):e3. PubMed ID: 30479087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
